Relay Therapeutics (RLAY) Competitors $3.62 +0.02 (+0.56%) Closing price 07/3/2025 02:34 PM EasternExtended Trading$3.62 0.00 (0.00%) As of 07/3/2025 04:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock RLAY vs. GMTX, IBRX, TWST, ARWR, APLS, VCEL, RXRX, NAMS, DNLI, and KNSAShould you be buying Relay Therapeutics stock or one of its competitors? The main competitors of Relay Therapeutics include Gemini Therapeutics (GMTX), ImmunityBio (IBRX), Twist Bioscience (TWST), Arrowhead Pharmaceuticals (ARWR), Apellis Pharmaceuticals (APLS), Vericel (VCEL), Recursion Pharmaceuticals (RXRX), NewAmsterdam Pharma (NAMS), Denali Therapeutics (DNLI), and Kiniksa Pharmaceuticals International (KNSA). These companies are all part of the "pharmaceutical products" industry. Relay Therapeutics vs. Its Competitors Gemini Therapeutics ImmunityBio Twist Bioscience Arrowhead Pharmaceuticals Apellis Pharmaceuticals Vericel Recursion Pharmaceuticals NewAmsterdam Pharma Denali Therapeutics Kiniksa Pharmaceuticals International Relay Therapeutics (NASDAQ:RLAY) and Gemini Therapeutics (NASDAQ:GMTX) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, dividends, earnings, valuation, institutional ownership, profitability, analyst recommendations and media sentiment. Do insiders & institutionals have more ownership in RLAY or GMTX? 97.0% of Relay Therapeutics shares are owned by institutional investors. Comparatively, 75.4% of Gemini Therapeutics shares are owned by institutional investors. 4.9% of Relay Therapeutics shares are owned by company insiders. Comparatively, 12.9% of Gemini Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth. Which has stronger valuation and earnings, RLAY or GMTX? Gemini Therapeutics has lower revenue, but higher earnings than Relay Therapeutics. Gemini Therapeutics is trading at a lower price-to-earnings ratio than Relay Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioRelay Therapeutics$10.01M62.00-$337.71M-$2.23-1.62Gemini TherapeuticsN/AN/A-$71.87M-$1.00-53.17 Do analysts rate RLAY or GMTX? Relay Therapeutics currently has a consensus price target of $17.67, suggesting a potential upside of 388.03%. Given Relay Therapeutics' stronger consensus rating and higher probable upside, research analysts clearly believe Relay Therapeutics is more favorable than Gemini Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Relay Therapeutics 0 Sell rating(s) 2 Hold rating(s) 10 Buy rating(s) 0 Strong Buy rating(s) 2.83Gemini Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Is RLAY or GMTX more profitable? Gemini Therapeutics' return on equity of -38.78% beat Relay Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Relay TherapeuticsN/A -44.17% -39.53% Gemini Therapeutics N/A -38.78%-35.88% Does the media refer more to RLAY or GMTX? In the previous week, Relay Therapeutics' average media sentiment score of 0.00 equaled Gemini Therapeutics'average media sentiment score. Company Overall Sentiment Relay Therapeutics Neutral Gemini Therapeutics Neutral Which has more risk & volatility, RLAY or GMTX? Relay Therapeutics has a beta of 1.62, meaning that its stock price is 62% more volatile than the S&P 500. Comparatively, Gemini Therapeutics has a beta of -0.12, meaning that its stock price is 112% less volatile than the S&P 500. SummaryRelay Therapeutics beats Gemini Therapeutics on 7 of the 12 factors compared between the two stocks. Get Relay Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for RLAY and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding RLAY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart RLAY vs. The Competition Export to ExcelMetricRelay TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$617.20M$2.43B$5.53B$8.95BDividend YieldN/A1.77%5.38%4.09%P/E Ratio-1.628.8627.4020.24Price / Sales62.00674.45417.66125.07Price / CashN/A157.0736.6357.47Price / Book0.784.638.085.67Net Income-$337.71M$31.34M$3.16B$248.47M7 Day Performance9.70%3.25%2.81%3.29%1 Month Performance12.07%6.80%3.69%5.18%1 Year Performance-42.26%1.89%35.30%21.35% Relay Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)RLAYRelay Therapeutics2.1512 of 5 stars$3.62+0.6%$17.67+388.0%-42.3%$617.20M$10.01M-1.62330GMTXGemini TherapeuticsN/A$54.50+0.7%N/A+27.8%$2.36BN/A-54.5030High Trading VolumeIBRXImmunityBio1.8886 of 5 stars$2.64-2.2%$12.25+364.0%-57.0%$2.33B$14.74M-4.55590Negative NewsGap UpTWSTTwist Bioscience4.4857 of 5 stars$36.79+2.4%$50.40+37.0%-20.6%$2.20B$312.97M-11.32990Positive NewsARWRArrowhead Pharmaceuticals3.9322 of 5 stars$15.80-1.7%$43.71+176.7%-33.1%$2.18B$3.55M-11.29400APLSApellis Pharmaceuticals4.5197 of 5 stars$17.31-0.7%$40.05+131.4%-49.2%$2.18B$781.37M-9.67770Trending NewsAnalyst ForecastAnalyst RevisionVCELVericel2.9247 of 5 stars$42.55+2.0%$61.14+43.7%-7.0%$2.14B$237.22M1,418.81300Positive NewsRXRXRecursion Pharmaceuticals2.13 of 5 stars$5.06+0.6%$7.00+38.3%-28.4%$2.06B$58.84M-2.86400Analyst ForecastNAMSNewAmsterdam Pharma3.0732 of 5 stars$18.11-2.5%$42.89+136.8%-0.8%$2.03B$45.56M-9.634Positive NewsDNLIDenali Therapeutics4.5373 of 5 stars$13.99-0.8%$33.71+141.0%-31.0%$2.03BN/A-5.24430KNSAKiniksa Pharmaceuticals International3.6953 of 5 stars$27.67-1.3%$38.80+40.2%+45.8%$2.02B$423.24M-110.68220 Related Companies and Tools Related Companies GMTX Alternatives IBRX Alternatives TWST Alternatives ARWR Alternatives APLS Alternatives VCEL Alternatives RXRX Alternatives NAMS Alternatives DNLI Alternatives KNSA Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:RLAY) was last updated on 7/4/2025 by MarketBeat.com Staff From Our PartnersWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | Sponsored379 passengers walked away from thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredElon just did WHAT!?As you may recall, Biden and the Fed were working on a central bank digital currency, or CBDC. Had they got...Brownstone Research | SponsoredCrypto Is Pumping Again – Now Comes the Real OpportunityThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredGold: Now legal tender in many statesThe perfect gold play right now? (currently under $10) Everything in the news now lines up perfectly for an...Stansberry Research | SponsoredTrump's ticking time bombA looming tariff deadline on July 9th could be the spark — but what’s buried inside a recent White House docum...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Relay Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Relay Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
